Emami Nashmil, Diamandis Eleftherios P
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Clin Chim Acta. 2007 May;381(1):78-84. doi: 10.1016/j.cca.2007.02.023. Epub 2007 Feb 20.
The human tissue kallikrein gene family, located at chromosome 19q13.4, is the largest contiguous family of proteases in the human genome. The locus encodes all 15 members of the family, 13 of which have been reported as potential biomarkers for several carcinomas and other non-neoplastic diseases. Kallikreins are expressed by a wide range of tissues and implicated in a number of physiological functions, including skin desquamation, semen liquefaction, neural plasticity and the regulation of blood pressure. Kallikrein function is regulated at various levels, including transcription, translation and post-translation. The proteolytic activity of kallikreins is believed to be cascade mediated and may cross-talk with other proteases. These cascades are highly regulated through a series of feedback loops, inhibitors, (auto) degradation and internal cleavage. Uncontrolled proteolytic activity of kallikreins is implicated in a large number of neoplastic and non-neoplastic pathological conditions.
As our understanding of their regulatory and functional mechanisms continues to expand, kallikreins are expected to become novel targets for the design of new therapeutics.
人组织激肽释放酶基因家族位于19号染色体q13.4区域,是人类基因组中最大的连续蛋白酶家族。该基因座编码该家族的所有15个成员,其中13个已被报道为多种癌症和其他非肿瘤性疾病的潜在生物标志物。激肽释放酶在多种组织中表达,并参与多种生理功能,包括皮肤脱屑、精液液化、神经可塑性和血压调节。激肽释放酶的功能在多个水平受到调节,包括转录、翻译和翻译后水平。激肽释放酶的蛋白水解活性被认为是级联介导的,并且可能与其他蛋白酶相互作用。这些级联通过一系列反馈环、抑制剂、(自)降解和内部切割受到高度调节。激肽释放酶不受控制的蛋白水解活性与大量肿瘤性和非肿瘤性病理状况有关。
随着我们对其调节和功能机制的理解不断扩展,激肽释放酶有望成为新型治疗药物设计的新靶点。